MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Akcijų sąrašas・Puma Biotechnology Inc

Puma Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

7.21 -3.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.17

Max

7.58

Pagrindiniai rodikliai
By Trading Economics
Pajamos	3M 12M
Pardavimai	21M 76M
P/E Sektoriaus vid.	12.41 63.808
Pelno marža	15.633
Darbuotojai	179
EBITDA	13M 27M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-33.16% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	27M 385M
Ankstesnė atidarymo kaina	10.3
Ankstesnė uždarymo kaina	7.21

Naujienos nuotaikos

By Acuity

50%

162 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

3.07 / 3.075 Palaikymas ir pasipriešinimas

Puma Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-16 23:26; UTC

Karštos akcijos

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026-04-16 20:41; UTC

Pagrindinės rinkos jėgos

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026-04-16 23:49; UTC

Rinkos pokalbiai

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026-04-16 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record High -- Market Talk

2026-04-16 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026-04-16 22:51; UTC

Rinkos pokalbiai

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026-04-16 22:08; UTC

Uždarbis

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Health Care Roundup: Market Talk

2026-04-16 20:49; UTC

Uždarbis

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026-04-16 20:43; UTC

Uždarbis

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Netflix Says Engagement Quality Hits New High -- Market Talk

2026-04-16 20:30; UTC

Karštos akcijos

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026-04-16 20:25; UTC

Uždarbis

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:23; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026-04-16 20:19; UTC

Uždarbis

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Akcijų palyginimas

Kainos pokytis

Puma Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

-33.16% į apačią

12 mėnesių prognozė

Vidutinis 5 USD -33.16%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Puma Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Puma Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.07 / 3.075Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

162 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.